SholoCARE is building precision therapeutic platforms that operate beyond the limits of conventional drugs — integrating small-molecule discovery, intracellular biologics, and adaptive antiviral systems.
3Therapeutic Platforms
3Disease Areas
∞Scalable Design
Our Discovery Engine
From biologics to small molecules
Our translation engine bridges the gap between complex intracellular biology and clinically viable, orally available therapeutics — starting from scFv, VHH, and peptide binders, ending in drug-like small molecules.
We don't compromise between power and deliverability. We engineer systems that achieve both.
Peptides to small molecules
SholoCARE's Small-Molecule Translation Engine identifies non-canonical binding sites and converts complex peptide binders into chemotypes designed for oral exposure and resistance awareness.
Problem & Mission
Most therapies fail not because disease drivers are unknown, but because they are unreachable.
SholoCARE was founded to overcome this barrier by developing therapeutic platforms capable of acting inside cells, adapting to biological complexity, and addressing diseases that evade today's static treatments.
We build platforms first and programs second, ensuring scalability across oncology, infectious disease, and emerging biological threats.
01
Act Inside Cells
Targeting disease biology where it actually lives — beyond the membrane barrier that conventional drugs cannot cross.
02
Adapt to Complexity
Systems designed not to fail when biology mutates or resistance develops — built with change in mind.
03
Scale Across Disease
Platforms that serve oncology, infectious disease, and emerging threats without being rebuilt from scratch.
Platform Vision
SholoCARE is advancing a new generation of therapeutic platforms.
We don't chase targets.We build systems that keep working when biology changes.
Let's build the future of medicine.
For more information about SholoCARE's programs please contact us.
From peptide insight to orally viable therapeutics
Reveals non-canonical regulatory binding sites
Translates complex binders into drug-like chemotypes
Designed for resistance awareness and oral exposure
Platform I
Small-Molecule Translation Engine
Discovery
Engineered to translate complex biological interactions into scalable, drug-like small molecules. Our engine bridges intractable biology and clinically viable therapeutics.
Non-canonical regulatory binding site discovery
Peptide-to-small-molecule translation pipeline
Resistance-aware molecular design framework
Oral bioavailability optimization at every stage
Platform II
CYTOPRISM™
Biologics
Intracellular Functional Biologics. CYTOPRISM™ enables direct modulation of intracellular targets using non-viral, non-integrating delivery — modular architecture built for function, not just binding.
Direct intracellular modulation of disease targets
Non-viral, non-integrating delivery mechanism
Function-first design philosophy
Modular architecture adaptable across target classes
Platform III
VIRTOPRISM™
Antiviral
Intracellular antiviral defense systems. VIRTOPRISM™ targets conserved viral components inside infected cells, with broad applicability and built-in mutation resilience — reconfigurable as threats evolve.
Targets conserved viral components inside cells
Broad applicability across enveloped virus families
Designed for mutation resilience
Rapid reconfiguration against emerging variants
The SholoCARE Difference
A new model for therapeutic development
Conventional Model
Single-asset focus
Static mechanisms
Delivery-limited
Narrow scope
SholoCARE Model
Multi-platform architecture
Intracellular functional strategies
Function-driven design
Cross-disease scalability
Cross-Platform Principles
Principles that unify our work
Intracellular SpecificityPrecision where biology operates — inside the cell, not around it.
Modularity & ReusePlatforms built to be repurposed across targets without being rebuilt.
Biological AdaptationSystems that remain effective as biology evolves and resists.
Scalable TranslationCross-disease applicability baked in from the discovery stage forward.
Ready to learn more?
For more information about SholoCARE's programs please contact us.
SholoCARE is a platform-driven biotechnology company focused on developing precision medicine systems capable of reaching disease biology beyond the limits of conventional medicines.
Who We Are
SholoCARE is a platform-driven biotechnology company focused on developing precision medicine systems capable of reaching disease biology beyond the limits of conventional medicines.
Our work spans oncology, infectious disease, and emerging biological threats — three areas united by a single challenge: reaching the biology that matters, reliably and at scale.
Scientific Leadership
SholoCARE is led by scientists with experience spanning molecular biology, therapeutic design, and translational execution.
Our team combines depth of expertise with a shared conviction: that the biggest barriers in medicine are not scientific unknowns, but engineering challenges waiting for the right platform.
Disease Focus
Two categories of unreachable biology
Our Philosophy
"Discover to Recover"
Discover to Recover reflects our belief that discovery must be deliberate, recovery requires precision, and meaningful medicine begins with reaching the right biology.
Evidence-BasedEvery decision anchored in data, not dogma.
Platform LeveragePrograms emerge from platforms — never the reverse.
Clear GatesDevelopment milestones that are honest, measurable, and respected.
Responsible RiskWe take the right risks — the ones science justifies.
Work with us.
For more information about SholoCARE's programs please contact us.
